{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-23-000006","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2023-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.957071+00:00","generated_at":"2026-06-19T08:03:47.196012+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"LivaNova: RECOVER depression trial enrollment extended to 475 unipolar patients","bullets":["Independent Statistical Analysis Committee advises to continue enrollment from 450 to 475 unipolar patients.","Trial uses interim analyses every 25 patients; predictive probability of success not yet reached.","Successful trial could support reconsideration of CMS reimbursement for VNS Therapy for difficult-to-treat depression.","After last RCT patient completes 12-month follow-up, final analysis will be conducted on complete dataset."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-23-000006","json":"https://secwatch.observer/filing/0001639691-23-000006.json","markdown":"https://secwatch.observer/filing/0001639691-23-000006.md","text":"https://secwatch.observer/filing/0001639691-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000006/0001639691-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969123000006/livn-20230217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:03:47.196012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}